iBio Inc (IBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31+0.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IBIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress IBIO-600 through Phase 1 clinical trial including single and multiple ascending dose portions to preserve muscle and improve body composition.
Stated as a priority in 2 of last 2 quarters. Management advanced IBIO-600 through the single ascending dose portion of its Phase 1 clinical trial, dosing 31 of 32 planned participants by 2026-Q2 and preparing to start the multiple ascending dose portion. The trajectory matches management's stated clinical development plan and is delivering progress toward clinical milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Advanced IBIO-600 through single ascending dose portion of Phase 1 clinical trial, dosing 31 of 32 planned participants.”
“Received clearance to initiate Phase 1 clinical trial of IBIO-600 with first participant dosing expected in 2Q 2026.”
Progress IBIO-610 for obesity and IBIO-800 bispecific antibody for PH-HFpEF through preclinical studies and IND-enabling development.
Stated as a priority in 2 of last 2 quarters. Management advanced IBIO-610 into IND-enabling studies with preclinical data showing 6.7% visceral fat and 5.2% total fat mass reduction in obese NHPs, and progressed IBIO-800 into IND-enabling development. The trajectory shows delivering preclinical progress supporting pipeline expansion.
“Advanced IBIO-610 into IND-enabling studies with preclinical data supporting fat-selective weight loss.”
“Presented new preclinical data for IBIO-610 demonstrating targeted fat reduction in obese NHPs.”
Appoint Molly Carr, M.D. as Chief Medical Officer to lead clinical strategy, medical affairs, and regulatory initiatives.
Newly stated in 2026-Q3 with the appointment of Molly Carr as Chief Medical Officer. This leadership addition aligns with management's focus on advancing clinical programs. No direct financial metrics apply, but the appointment supports execution capability.
Raise capital via public offering, private placement, and warrant exercises to extend cash runway into Q4 fiscal 2028.
Stated in 2 of last 2 quarters. Management closed a $100M public offering in Aug 2025, a $26M private placement in Jan 2026, and received warrant exercise proceeds extending cash runway into Q4 fiscal 2028. Cash and investments rose from $9.7M in 2025-Q4 to $92.2M in 2026-Q2, delivering on capital extension priorities.
“Closed $100M public offering in Aug 2025 and $26M private placement in Jan 2026; cash runway extended into Q4 fiscal 2028.”
“Cash, cash equivalents and investments totaled $74.8M as of March 31, 2026.”
Control operating expenses and losses while advancing R&D and administrative functions.
Stated in 2 of last 2 quarters. Operating loss increased from $18.6M in fiscal 2025 to $35.1M in fiscal 2026, driven by R&D expense growth from $8.3M to $19.6M. Management emphasizes disciplined financial execution despite higher expenses. The trajectory shows increased losses consistent with advancing pipeline but requires ongoing cost management.
“Paired significant scientific progress with disciplined financial execution, strengthening balance sheet.”
“Operating loss increased to $35.1M in fiscal 2026 from $18.6M in fiscal 2025 due to higher R&D expenses.”
Over the trailing year it converted 0.92x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
23 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.